|
|
|
| A Study on the Long-term Effects and Related Factors of Adjuvant Chemotherapy after Surgery in Patients with Stage IB-IIA Cervical Cancer and Recurrence Risk Factors |
| Zhou Tong, Dong Guoling, Ma Qimin |
| Department of Gynecology, Anyang Maternal and Child Health Hospital Anyang, Henan 455000 |
|
|
|
|
Abstract Objective To investigate the long-term efficacy of adjuvant chemotherapy after surgery in patients with stage IB-IIA cervical cancer and potential risk factors for recurrence,and to analyze the prognostic factors. Methods A retrospective analysis was conducted on the data of 162 patients with stage IB-IIA cervical cancer and potential risk factors for recurrence admitted to our hospital from January 2019 to January 2022.All patients underwent radical hysterectomy.Patients were divided into a chemotherapy group(n=89) and a control group(n=73) based on whether they received adjuvant chemotherapy after surgery.The chemotherapy group received adjuvant chemotherapy with paclitaxel combined with cisplatin,while the control group received only routine follow-up.A 3-year follow-up was conducted,and the progression-free survival(PFS) rate and overall survival(OS) rate of the two groups were recorded in detail.Logistic regression analysis was used to explore the relevant factors affecting the long-term prognosis of the patients. Results After 3 years of follow-up,the PFS rate in the chemotherapy group was 84.27%(75/89),and the OS rate was 87.60%(78/89),while the PFS rate in the control group was 63.01%(46/73),and the OS rate was 75.34%(55/73).The 3-year PFS and OS rates in the chemotherapy group were significantly higher than those in the control group(P<0.05).Poorly differentiated tumors,lymph node metastasis,vascular invasion,and tumor diameter≥4cm were risk factors affecting the 3-year PFS and OS rates(P<0.05),while adjuvant chemotherapy after surgery was a protective factor. Conclusion For patients with stage IB-IIA cervical cancer and recurrence risk factors,adjuvant chemotherapy after surgery can significantly improve their long-term PFS and OS rates and improve prognosis.Furthermore,poor tumor differentiation,lymph node metastasis,vascular invasion,and tumor diameter affect the long-term prognosis of patients.
|
|
Received: 01 April 2026
|
|
|
|
|
|
[1] 王玲娜,吴丹红,方主未,等.2021年浙江省肿瘤登记地区宫颈癌发病、死亡现状及2000-2021年变化趋势[J].中国肿瘤,2026,35(1):41-47.
[2] Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
[3] Han B,Zheng R,Zeng H,et al.Cancer incidence and mortality in China,2022[J].J Natl Cancer Cent,2024,4(1):47-53.
[4] 王孟菲,许波群.局部晚期宫颈癌免疫治疗进展[J].实用肿瘤学杂志,2025,39(2):157-161.
[5] 张妙琴,李伟华,卫丹,等.局部晚期子宫颈癌根治性放化疗后复发进展风险预测列线图模型构建[J].转化医学杂志,2026,15(1):105-111.
[6] 宁显璞,张永军,王定伦,等.FIGO分期系统改变后Ⅰb3、Ⅱa2期宫颈癌不同治疗方式的预后分析[J].现代妇产科进展,2024,33(10):728-734.
[7] 陈露露,冯成军,陈绍俊.辅助化疗在宫颈癌中的研究现状和进展[J].肿瘤学杂志,2025,31(11):923-929.
[8] 王娇,何玥,杨淑丽,等.铂类为基础新辅助化疗联合手术治疗局部晚期宫颈癌的生存和生活质量研究[J].中国医刊,2024,59(11):1257-1260.
[9] 陈开明,白正英,魏鑫.Ⅰb~Ⅱa期宫颈癌行腹腔镜下广泛性子宫切除联合淋巴结清扫术后远期预后影响因素[J].中国计划生育学杂志,2025,33(7):1651-1655.
[10] 李思奇,王锐晨,郑晔,等.伴有淋巴结转移的宫颈癌患者治疗与生存预后临床分析[J].中国妇产科临床杂志,2025,26(5):388-391. |
| [1] |
Ju Xinjie, Guo Gang, Zhang Weihua. Effects of High Sensitivity C-reactive Protein and Homocysteine on Neurological Deficit and Prognosis in Patients with Acute Cerebral Infarction[J]. journal1, 2026, 46(5): 9-12. |
| [2] |
. [J]. journal1, 2026, 46(5): 69-71. |
| [3] |
. [J]. journal1, 2026, 46(5): 98-102. |
| [4] |
. [J]. journal1, 2026, 46(5): 103-106. |
| [5] |
Wang Yiting, Lin Shenghua. Application of Combined Detection of Serum SAA,CRP and NLR Levels in the Prognostic Evaluation of Patients with Bacterial Pneumonia in the Short Term[J]. journal1, 2026, 46(4): 1-4. |
| [6] |
Chen Qiuning. Survey and Analysis of Perinatal Risk Factors and Outcomes in Hospitalized Preterm Infants in Southern Hainan[J]. journal1, 2026, 46(4): 35-37. |
|
|
|
|
2026, Vol. 46 
